Frequently Asked Questions About CMV Management

In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:Evaluation of current data on CMV prevention in liver transplant recipientsPractical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxisBarrier of resistance to antiviral therapiesFactors to consider when deciding CMV treatment durationUse of lymphocyte count to assess CMV cell–mediated immunityProgram Director:Atul Humar, MD, FRCP(C)Professor of MedicineUniversity of Toronto  Director, Ajmera Transplant CentreUniversity Health NetworkR. Fraser Elliott Chair in TransplantationDirector University of Toronto Transplant InstituteToronto, Ontario, CanadaFaculty:Hannah Imlay, MD, MSAssistant Professor of MedicineDepartment of Internal Medicine, Division of Infectious DiseasesUniversity of Utah  Salt Lake City, UtahRaymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota  Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K